6OD.F ODI PHARMA AB
- Market cap
- EUR 3.30M
- P/E
- 18.0x
- P/B
- 15.28x
- ROE
- 83.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 6OD.F undervalued?
Graham numberThe Graham number of ODI PHARMA AB cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ODI PHARMA AB fundamental analysis
No fundamental analysis for ODI PHARMA AB yet.
ODI PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.
Full company profileODI PHARMA AB financial statements
ODI PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 313K | 139K | 22.3M | 3.13M | 32.9M |
| Gross Profit | -104K | -718K | 4.62M | 839K | 10.3M |
| Operating Income | -7.21M | -6.81M | 428K | -5.45M | 2.50M |
| EBITDA | - | -6.78M | 479K | -5.19M | 2.60M |
| Net Income | -7.24M | -6.90M | -568K | -5.93M | 1.99M |
| EPS | -0.47 | -0.45 | -0.04 | -0.32 | 0.11 |
| Balance Sheet | |||||
| Total Assets | 10.5M | 8.19M | 12.2M | 4.61M | 5.30M |
| Total Liabilities | 1.24M | 5.61M | 10.2M | 4.19M | 2.93M |
| Shareholders' Equity | 9.26M | 2.57M | 2.00M | 425K | 2.38M |
| Cash & Short-term Investments | 7.37M | 6.49M | 2.64M | 1.48M | 3.39M |
| Cash Flow | |||||
| Operating Cash Flow | -7.37M | -5.10M | -3.82M | -3.31M | 4.58M |
| Capital Expenditure | 4.11K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -7.38M | -5.10M | -3.82M | -3.31M | 4.58M |
| Ratios | |||||
| ROE | -78.2% | -268.2% | -28.4% | -1,397.3% | 83.7% |
| ROA | -69.0% | -84.3% | -4.6% | -128.7% | 37.5% |
| Net Profit Margin | -2,313.2% | -4,948.6% | -2.5% | -189.3% | 6.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ODI PHARMA AB dividends
ODI PHARMA AB has not paid dividends in the last 5 fiscal years.
Who owns ODI PHARMA AB
- Insiders 89.98%
- Institutions 0.00%
- Public & others 10.02%
- Shares outstanding 18.3M
- Free float 1.84M
ODI PHARMA AB company profile
- Company name
- ODI PHARMA AB
- Ticker
- 6OD.F
- ISIN
- SE0013409760
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1
- Fiscal year end
- June
- Address
- Oestermalmstorg 1, Stockholm, Sweden, 114 42
- Website
- odipharma.com
About ODI PHARMA AB
ODI Pharma AB (publ), a pharmaceutical company, engages in the production and distribution of pharmaceutical cannabis and cosmetics products in Europe. It offers dried flowers; and cosmetics products. ODI Pharma AB (publ) was founded in 2018 and is based in Stockholm, Sweden.
ODI PHARMA AB management
4- Mr. Jan-Mark EdewaardCEO & Director
- Ms. Karina KilinskiSales Manager & Director
- Dr. Markus FritzscheHead of Research
- Thomas CramerHead of Sales Cosmetics